RxSight, Inc.

RxSight, Inc. is a U.S.-based medical technology company focused on cataract surgery. Its proprietary RxSight system combines the Light Adjustable Lens with a Light Delivery Device and related accessories to let surgeons adjust a patient’s lens power after implantation. The company operates through a commercial organization and subsidiaries in Hong Kong and Europe to support sales and expansion outside the United States.

−33,4 %

76,6 %

−29,0 %

−3,9 %

10.95

9.75

— RxSight, Inc.
%
Light Adjustable Lenses65% Premium intraocular lenses implanted during cataract surgery and later adjusted with UV light.
Light Delivery Devices20% Capital devices installed in practices to deliver the light used to adjust the lens after surgery.
Accessories and consumables10% Ancillary items used with the lens and device during treatment and follow-up.
Service and warranty5% Installation, training, warranty, and ongoing service tied to the LDD base.

RxSight sells primarily to ophthalmic practices and ambulatory surgery centers involved in cataract surgery...

  • Ophthalmic practicesprimary

    Buy LDD systems, training, and support to perform postoperative lens adjustments and grow premium cataract volume.

  • Ambulatory surgery centersprimary

    Buy LALs used in cataract procedures and participate in premium IOL workflows.

  • Cataract surgeonsprimary

    Use the system to customize refractive outcomes after surgery and improve patient satisfaction.

  • Patients undergoing cataract surgerysecondary

    Ultimately receive the implanted lens and adjustment process, seeking better visual outcomes.

  • International distributors and healthcare providersemerging

    Support selective non-U.S. commercialization in approved markets.

RxSight primarily generates revenue in the United States, where it focuses its commercial organization and installed...

  • •United States is the core commercial market and main revenue source
  • •Europe, Canada, Mexico, Singapore, Australia, and South Korea are approved markets
  • •Hong Kong and Netherlands subsidiaries support international operations
  • •UK branch and German subsidiary extend European presence
  • •Non-U.S. reimbursement rules vary and affect adoption speed

RxSight’s strategy centers on expanding adoption of the Light Adjustable Lens system, increasing the installed base of...

01
Grow LAL adoption and utilizationshort-term

Higher lens utilization drives recurring procedure volume and deepens account penetration.

02
Expand the LDD installed basemedium-term

More installed devices create a larger footprint for future LAL usage and service revenue.

03
Enhance the product platformmedium-term

Software, lens, and manufacturing improvements can improve outcomes and adoption.

04
Selective international expansionlong-term

Approved foreign markets broaden the long-term addressable market beyond the U.S.

RxSight depends on adoption of a specialized surgical workflow, regulatory approvals, and effective training of doctors...

high

Regulatory approval delays or denials

Commercialization and new indications depend on maintaining and expanding clearances in multiple jurisdictions.

Scope
U.S. and international product approvals
Materiality
high
high

Supply chain concentration

Dependence on third parties and single/sole source suppliers can disrupt production and raise costs.

Scope
LAL and LDD components and subcomponents
Materiality
high
high

Intellectual property leakage or invalidation

The system depends on proprietary lens material, device design, and trade secrets.

Scope
Global patent and trade secret portfolio
Materiality
high
medium

Slow adoption of a new surgical workflow

Doctors must learn a new procedure and train staff, which can limit penetration versus conventional IOLs.

Scope
U.S. cataract practices and surgery centers
Materiality
high
medium

Competition in premium IOLs

Alternative lenses and surgical technologies can limit market share and pricing power.

Scope
Premium cataract surgery market
Materiality
high
Revenue recognition by product type
Point-in-time vs over-time recognition
Consignment inventory
Timing of product revenue
Bundled LDD arrangements
Revenue allocation and deferral
Warranty and service estimates
Gross margin and liabilities
Stock-based compensation
Operating expense and dilution

LENSAR, Inc.

LNSR · Surgical & Medical Instruments & Apparatus

LENZ Therapeutics, Inc.

LENZ · Biological Products, (No Diagnostic Substances)

STAAR SURGICAL CO

STAA · Ophthalmic Goods

RetinalGenix Technologies Inc.

RTGN · Surgical & Medical Instruments & Apparatus

Sight Sciences, Inc.

SGHT · Surgical & Medical Instruments & Apparatus

ESCALON MEDICAL CORP

ESMC · Electromedical & Electrotherapeutic Apparatus

: 29/04/2026